ATE210447T1 - Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen - Google Patents

Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen

Info

Publication number
ATE210447T1
ATE210447T1 AT95935444T AT95935444T ATE210447T1 AT E210447 T1 ATE210447 T1 AT E210447T1 AT 95935444 T AT95935444 T AT 95935444T AT 95935444 T AT95935444 T AT 95935444T AT E210447 T1 ATE210447 T1 AT E210447T1
Authority
AT
Austria
Prior art keywords
cck
sleep disorders
receptor antagonists
treat sleep
treat
Prior art date
Application number
AT95935444T
Other languages
English (en)
Inventor
Emiliangelo Ratti
David Gordon Trist
Giovanni Gaviraghi
Francesco Crespi
Angelo Mario Reggiani
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9420703A external-priority patent/GB9420703D0/en
Priority claimed from GB9420704A external-priority patent/GB9420704D0/en
Priority claimed from GB9423098A external-priority patent/GB9423098D0/en
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Application granted granted Critical
Publication of ATE210447T1 publication Critical patent/ATE210447T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95935444T 1994-10-14 1995-10-12 Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen ATE210447T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9420703A GB9420703D0 (en) 1994-10-14 1994-10-14 Medicament
GB9420704A GB9420704D0 (en) 1994-10-14 1994-10-14 Medicaments
GB9423098A GB9423098D0 (en) 1994-11-16 1994-11-16 Medicaments
PCT/EP1995/004024 WO1996011689A1 (en) 1994-10-14 1995-10-12 Use of cck-b receptor antagonists for the treatment of sleep disorders

Publications (1)

Publication Number Publication Date
ATE210447T1 true ATE210447T1 (de) 2001-12-15

Family

ID=27267429

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95935444T ATE210447T1 (de) 1994-10-14 1995-10-12 Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen

Country Status (9)

Country Link
US (1) US6413930B1 (de)
EP (1) EP0785788B1 (de)
JP (1) JPH10511928A (de)
AT (1) ATE210447T1 (de)
AU (1) AU3745795A (de)
DE (1) DE69524623T2 (de)
ES (1) ES2171196T3 (de)
IL (1) IL115589A0 (de)
WO (1) WO1996011689A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2239293A1 (en) 1995-12-11 1997-06-19 New England Medical Center Hosptials, Inc. Assay for and uses of peptide hormone receptor ligands
US5750353A (en) * 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
WO1998000406A1 (en) * 1996-07-02 1998-01-08 Merck & Co., Inc. Method for the treatment of preterm labor
US5929071A (en) * 1996-07-02 1999-07-27 Merck & Co., Inc. Method for the treatment of preterm labor
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
GB0310864D0 (en) * 2003-05-12 2003-06-18 Black James Foundation Gastrin and cholecystokinin receptor ligands
US20040234914A1 (en) 2003-05-21 2004-11-25 Alexza Molecular Delivery Corporation Percussively ignited or electrically ingnited self-contained heating unit and drug-supply unit employing same
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US7581540B2 (en) 2004-08-12 2009-09-01 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
KR102852740B1 (ko) 2018-02-02 2025-08-29 알렉스자 파마스티칼즈, 인크. 전기적 응축 에어로졸 디바이스

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950664A (en) * 1988-09-16 1990-08-21 Rugby-Darby Group Companies, Inc. Nasal administration of benzodiazepine hypnotics
EP0558104B1 (de) 1992-01-21 1998-07-29 GLAXO WELLCOME S.p.A. 1,5-Benzodiazepinderivate und deren Verwendung in Heilmittel
TW213901B (de) 1992-01-27 1993-10-01 Pfizer

Also Published As

Publication number Publication date
EP0785788A1 (de) 1997-07-30
DE69524623T2 (de) 2002-08-08
US6413930B1 (en) 2002-07-02
IL115589A0 (en) 1996-01-19
DE69524623D1 (de) 2002-01-24
ES2171196T3 (es) 2002-09-01
JPH10511928A (ja) 1998-11-17
AU3745795A (en) 1996-05-06
WO1996011689A1 (en) 1996-04-25
EP0785788B1 (de) 2001-12-12

Similar Documents

Publication Publication Date Title
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE69726724D1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
ATE207356T1 (de) Verwendung von tiagabin zur behandlung von schlafstörungen
ATE209047T1 (de) Epoxysteroide aldosteronantagonist und angiotensin ii rezeptor antagonist kombinationstherapie zur behandlung von congestivem herzversagen
ATE365042T1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69925571D1 (de) Sulphonamid-derivate zur behandlung von störungen des zentralnervensystems
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
DE3780972D1 (de) Verwendung von spezifischen n-methyl-d-aspartat-rezeptor-antagonisten zur praevention und behandlung von neurodegeneration.
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE69738613D1 (de) Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
DE69634951D1 (de) Topische verwendung von betulinsäure zur behandlung bösartiger melanome
DE59810761D1 (de) Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres
ATE158183T1 (de) Arzneimittel zur behandlung von anxietas
DE69825286D1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
DE69432595D1 (de) Antagonisten des angiotensin ii-rezeptors zur behandlung von chronischen entzündlichen erkrankungen
ATE221763T1 (de) Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
DE59209728D1 (de) VERWENDUNG VON ANTAGONISTEN ODER PARTIELLEN AGONISTEN AM 5-HT 1a-REZEPTOR ZUR BEHANDLUNG UND PRÄVENTION VON KOGNITIVEN STÖRUNGEN
ATE269705T1 (de) Verwendung von optisch reinem (r)-tofizopam zur behandlung und pravention von angststörungen
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties